cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
almogran 12.5 mg
almirall, s.a. - almotriptanmalat - tablett, filmdrasjert - 12.5 mg
sunitinib newbury 50 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 50 mg
sunitinib newbury 12.5 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 12.5 mg
sunitinib newbury 25 mg
newbury pharmaceuticals ab - sunitinibmalat - kapsel, hard - 25 mg
almotriptan orifarm 12.5 mg
orifarm generics a/s - almotriptanmalat - tablett, filmdrasjert - 12.5 mg
aqumeldi
proveca pharma limited - enalapril (maleate) - hjertefeil - agenter som virker på renin-angiotensinsystemet - treatment of heart failure.
enalapril comp ratiopharm 20 mg / 12.5 mg
ratiopharm gmbh - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg
co-renitec 20 mg / 12.5 mg
orifarm as - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg
renitec comp 20 mg / 12.5 mg
n.v. organon - kloosterstraat - enalaprilmaleat / hydroklortiazid - tablett - 20 mg / 12.5 mg